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Abstract
Chronic infantile neurological cutaneous and articular syndrome (CINCA), also known as neonatal-onset
multisystem inﬂammatory disease (NOMID), is a dominantly inherited systemic autoinﬂammatory disease
and is causedbya heterozygous germline gain-of-function mutation in the NLRP3 gene. We recently found a
high incidence of NLRP3 somatic mosaicism in apparently mutation-negative CINCA/NOMID patients using
subcloningandsubsequentcapillaryDNAsequencing.ItisimportanttorapidlydiagnosesomaticNLRP3mo-
saicism to ensure proper treatment. However, this approach requires large investments of time, cost, and
labour that prevent routine genetic diagnosis of low-level somatic NLRP3 mosaicism. We developed a
routinepipelinetodetectevenalow-levelalleleofNLRP3withstatisticalsigniﬁcanceusingmassivelyparallel
DNA sequencing.Toaddressthecriticalconcern ofdiscriminatinga low-levelallele fromsequencingerrors,
we ﬁrst constructed error rate maps of 14 polymerase chain reaction products covering the entire coding
NLRP3 exons on a Roche 454 GS-FLX sequencer from 50 control samples without mosaicism. Based on
these results, we formulated a statistical conﬁdence value foreach sequence variation in each strand to dis-
criminatesequencing errorsfrom realgenetic variation evenin alow-level allele, and therebydetected base
substitutions at an allele frequency as low as 1% with 99.9% or higher conﬁdence.
Key words: next generation sequencing; mosaicism; DNA diagnosis; chronic infantile neurological cutaneous
and articular syndrome
1. Introduction
Chronic infantile neurological cutaneous and ar-
ticular syndrome (CINCA; MIM #607115), also
known as neonatal-onset multisystem inﬂammatory
disease (NOMID), is a dominantly inherited autoin-
ﬂammatory disease that is characterized by neonatal
onset and a triad of symptoms, including an urticar-
ial-like skin rash, neurological manifestations, and
arthritis/arthropathy.
1–3 Patients often experience
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NOMID is the most severe clinical phenotype in the
spectrum of cryopyrin-associated periodic syndromes
(CAPS), which also include two less severe but pheno-
typically similar syndromes, familial cold autoinﬂam-
matory syndrome (FCAS; MIM #120100), and
Muckle2Wells syndrome (MWS; MIM #191900).
CAPS are caused by mutations in the NLRP3 gene,
which is a member of the Nod-like receptor (NLR)
family of the innate immune system.
4–6
Approximately 60% of CINCA/NOMID patients
carry heterozygous germline missense mutations in
the NLRP3 coding region (mutation-positive
patients).
7 More than 80 different disease-causing
mutations have been reported to date.
8 However,
the remaining clinically diagnosed CINCA/NOMID
patients (40%) show no heterozygous germline
NLRP3 mutation based on conventional DNA sequen-
cing-based genetic analyses (mutation-negative
patients). In a previous international collaborative
study, we found that there was a high incidence of
somatic NLRP3 mosaicism in mutation-negative
CINCA/NOMID patients worldwide.
9 The level of mo-
saicism ranges from 4.2 to 35.8% (median ¼ 10.2%).
Rapidly diagnosing somatic NLRP3 mosaicism is
important to ensure proper treatment. However, the
conventional approach used to identify somatic
mosaicism of the NLRP3 gene is time and labour
intensive due to the subcloning of the NLRP3 exon
polymerase chain reaction (PCR) products, hereafter
designated as amplicons, followed by capillary DNA
sequencing of more than 100 subclones for each
patient. Thus, this approach is not suitable to routine-
ly diagnose somatic mosaicism of the NLRP3 gene and
additional labour and time will be required to reliably
identify somatic mosaicism that occurs at a lower rate.
The aim of the present study was to establish a new
method that can be used to reliably diagnose
somatic mosaicism using the NLRP3 gene as a
model. Massively parallel DNA sequencing (MPS)
technology is an obvious method of choice to identify
somatic mosaicism, and this approach has been
already reported by other groups.
10–12 However, a
well-known caveat of MPS is the high rate of sequen-
cing errors, which cannot be disregarded when iden-
tifying low-level somatic mosaicism. To our
knowledge, there have been no reports of a reliable
method to discriminate MPS sequencing errors from
somatic mosaicism with statistical conﬁdence.
In this study, we ﬁrst analysed the patterns of
sequencing errors in NLRP3 coding exons at a single-
residue resolution by MPS using a Roche 454 GS-FLX
sequencer and then constructed an error rate map
for each base position in the NLRP3 exons. Based on
the error rate map, we could formulate a discrimin-
ation pipeline of somatic mosaicism from sequencing
errors and thereby detect new somatic mosaicism in
mutation-negative CINCA/NOMID patients, whose
somatic mutations were subsequently conﬁrmed by
subcloning and Sanger sequencing. This approach
can also be generally used to identify low-level
somatic mosaicism in other genes.
2. Patients and methods
2.1. Patients and DNA materials
Patients were clinically diagnosed with CAPS by
their referring physicians and the NLRP3 gene was
examined using the conventional Sanger sequencing
method. DNA samples were obtained from Japanese
NLRP3 somatic mosaic patients (n ¼ 5) who have
been previously described,
9,13 CAPS patients (n ¼ 5)
with heterozygous NLRP3 mutations, and healthy
donors (n ¼ 50). Genomic DNA samples from muta-
tion-negative CINCA/NOMID patients (n ¼ 10) were
obtained from the National Institute of Health,
Bethesda, USA. To generate DNA samples with no
mosaicism, we constructed a set of subcloned plas-
mids containing each exon and its ﬂanking intronic
regions in the NLRP3 gene from healthy donor
genomic DNA using a Topo TA cloning kit
(Invitrogen, San Diego, CA, USA). The cloned plasmids
containing each exon and the ﬂanking regions were
validated by Sanger sequencing. Written informed
consent was obtained from all the patients and their
families. The study was approved by the ethical com-
mittees of Kyoto University and Kazusa DNA Research
Institute and was conducted in accordance with the
Helsinki Declaration.
2.2. MPS of NLRP3 gene amplicons
Genomic DNA samples were extracted from whole
blood or peripheral blood mononuclear cells as previ-
ously described. We used a two-step PCR assay and
pooled sample libraries for MPS. To cover the entire
NLRP3 coding exonic regions and ﬂanking intronic
regions, 14 amplicons were designed to be as long
as an average read length for a 454 GS-FLX sequencer
(up to 450 bases) and then ampliﬁed from each
genomic DNA sample (Fig. 1A). The sequences of
the PCR primers that were used to generate these
14 amplicons are provided in Supplementary Table
S1. The upper and lower amplicon-speciﬁc primer
sequences were ﬂanked by common 15-base
adapter sequences (TGTAAAACGACGGCC and GGAAA
CAGCTATGAC for the upper and lower primers, re-
spectively) at the 50 end in order to fuse the primer-
binding sequence for MPS in the second-step PCR.
The ﬁrst PCR ampliﬁcations were performed in
50-ml reactions using 30 ng of genomic DNA,
1  PrimeSTAR GXL buffer, 0.2 mM of each dNTP,
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1.25 U of PrimeSTAR GXL DNA polymerase (Takara
Bio, Shiga, Japan). The thermal cycling proﬁle con-
sisted of an initial denaturation step at 988C for
1 min, followed by 28–32 cycles of 10 s denaturation
at 988C, 15 s of annealing at 608C, and a 30 s exten-
sion at 688C. The lengths of the PCR products ranged
from 291 to 421 bp. The second PCR ampliﬁcations
were performed using primers with adapter
sequences at the 30 end and Multiplex Identiﬁer
(MID) sequences at the 50 end (Fig. 1B), which was
used as a tag for each sample. The PCR reactions
were performed in 50-ml volumes using 0.5 mlo f
the ﬁrst PCR products, 1  PrimeSTAR GXL buffer,
0.2 mM of each dNTP, 12.5 pmol of each forward
and reverse primer, and 1.25 U of PrimeSTAR GXL
Figure 1. The amplicon analysis for NLRP3 exons and its error rate. (A) Exon–intron structure of the NLPR3 gene. Thick and thin rectangles
depict exons and introns, respectively. Blue thick rectangles indicate the CDS region. The 14 designed amplicons (red) for nine exons are
shown under the exon–intron structure. (B) Amplicon design schema. (C) Error rate for each error category in the region of entire
amplicon (pale blue), that without designed primer regions (light blue), and the target regions (CDS þ ﬂanking intron; dark blue),
respectively. (D) Strand-wise error rate for each amplicon. (E) Error rates along the amplicon sequence of exon 1 in each strand for
insertions and deletions in the upper panel and mismatches and ambiguous base calls in the lower panel. The orange and blue lines
depict the primer and target regions, respectively. The yellow shaded area depicts the homonucleotide (n . 3) region. The colour
representation for the bars is the same as (D). (F) Co-occurrence error rate in both strands. The fraction of positions where a certain
error occurred with the error rate for insertions, deletions, and mismatches. The colour representation is the same as in (D) and (E).
No. 2] K. Izawa et al. 145DNA polymerase to attach the anchor sequences for
MPS. The thermal cycling proﬁle consisted of an
initial denaturation step at 988C for 20 s, followed
by 20 cycles of 10 s denaturation at 988C, 15 s of
annealing at 608C, and a 40 s extension at 688C.
After conﬁrming the amount and integrity of the
PCR products by agarose gel electrophoresis, we
mixed virtually equal amounts of the respective PCR
amplicons that were generated using the same
genomic DNA and applied the samples to a 454
Genome Sequencer (GS)-FLX system (Roche
Diagnostics Corp., USA). All amplicons were ampliﬁed
by emPCR and sequenced together in a multiplex
fashion. MPS on this platform was performed as
instructed by Roche. The sequencing reads from
each of the pooled libraries were identiﬁed by their
MID tags.
2.3. Sequence data analysis
The sequence read data were generated using GS
RunProcessor ver.2.5.3 with default settings. Reads
were sorted according to the MID tag sequences and
were mapped to the reference amplicon sequences
using the BLAT program
14 with the ‘-ﬁne’ option. In
order to identify positions where the bases in a read
differed from those in the reference sequence, each
read was aligned to its reference sequence with the
dpAlign module in the BioPerl package (http://www.
bioperl.org/). The 454 pyrosequencing-related
errors were categorized as insertions, deletions, mis-
matches, or ambiguous base calls. When aligning
sequences, insertions/deletions are allocated based
on the sequence context and strand orientation. To
eliminate alignment artefacts due to insertion/dele-
tion positions, the lower strand reads were converted
to the reverse complement sequence, i.e. keeping the
same strandness as the upper strand reads, when
aligned with the reference sequence. A sequence
error was deﬁned as discordance in an equivalent pos-
ition between the reference and control (from the 49
healthy individuals and a cloned plasmid vector). The
error rate for a speciﬁed category was deﬁned as the
number of errors divided by the total number of
bases in a read. The error rates of a base position on
each strand were calculated from 50 control samples.
2.4. Conﬁrmation of somatic mosaicism of the NLRP3
gene by subcloning and subsequent capillary DNA
sequencing
To conﬁrm the somatic mutational frequency that
was identiﬁed based on the 454 sequencing data,
we subcloned the PCR products and performed capil-
lary DNA sequencing as previously described.
9 ATopo
TA cloning kit (Invitrogen, San Diego, CA, USA) was
used to subclone each of the 14 amplicons.
2.5. Functional analysis
To determine whether the identiﬁed NLRP3
mutants are disease-causing, we assessed both ASC
[apoptosis-associated speck-like protein containing a
caspase recruitment domain; PYCARD, an approved
symbol from the HUGO Gene Nomenclature
Committee (HGNC) database]-dependent NF-kB acti-
vation in HEK293FT cells and transfection-induced
cell death in THP-1 cells, a human monocytic cell
line, as previously described.
9,13,15 cDNAs encoding
carboxy-terminal green ﬂuorescent protein (GFP)-
tagged NLRP3 and its mutants were subcloned into
pcDNA5/TO (Invitrogen). Before being introduced
into THP-1 cells (10
6) using a Cell Line Nucleofector
Kit V (Amaxa Biosystems, Cologne, Germany),
phorbol myristate acetate (10 ng/ml) was added to
enhance transient expression of NLRP3 genewith min-
imizing spontaneous cell death.
15 Four hours after the
introduction of plasmids (0.5 mg), cell death of GFP-
positive THP-1 cells was measured by ﬂow cytometry.
Expression plasmids for NLRP3 and ASC in the
pEF-BOS vector background have been previously
described.
13 HEK293FT cells (10
5) were transfected
using TransIT-293 Transfection Reagent (Milus Bio,
Madison, WI, USA) with an NF-kB reporter construct
(pNF-kB-luc; 20 ng; BD Biosciences Clontech, Palo
Alto, CA, USA), an internal control construct (pRL-
TK; 5 ng; Toyo Ink, Tokyo, Japan), and wild-type or
mutant NLRP3 expression plasmid (20 ng) in the
presence or absence of ASC expression plasmid
(20 ng). The amounts of total plasmid DNA used for
transfection experiments were kept constant by
adding pEF-BOS vector DNA. Twenty-four hours
later, the transfected cells were harvested and sub-
jected to dual luciferase assay by which the ability of
each construct to induce NF-kB activation was
assessed as previously described.
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3. Results
3.1. Construction of base- and strand-speciﬁc error
rate maps of NLRP3 exons from the MPS
data of 50 control samples
Errors in sequence reads generated by a Roche 454
GS-FLX sequencer are not randomly distributed along
the sequence and depend on various factors.
16
Although this is a well-known characteristic of 454 se-
quencing, the occurrence pattern of these errors has
not been explored in detail simply because these
sequencing errors are considered noise that can be
ﬁltered out in most cases. However, it is highly critical
to understand the occurrence pattern of sequencing
errors on the MPS platform because low-level somatic
mosaicism might appear at a rate close to that of se-
quencing errors. To address this, we collected
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quencer for 14 amplicons of NLRP3 exons from 50
control samples that were thought to be free from
somatic mosaicism, and 94% of those reads were
mapped to one of the reference NLRP3 exon
sequences. The number of sequencing depths for
each amplicon of each sample on each strand was
between 65 and 2139 (mean ¼ 565.3,
Supplementary Table S2). We found that the average
error rate for each mutation category (insertion, dele-
tion,mismatch,andambiguousbasecalls)ateachbase
position on each strand of the amplicons in the control
samples was 0.22, 0.16, 0.036, and 0.014%, respect-
ively (Fig. 1C). These values were consistent with
those reported in a recent study on the error rates
with 454 sequencing data.
16 The sequencing error in
the 454 GS-FLX system tendsto occuratthe beginning
and end of the reads,
11,16 and we conﬁrmed this trend
in our amplicon sequencing data (Supplementary Fig.
S1). Moreover, after removing the end regions of the
read sequences, we found that the error rates of the
target regions for each category were 0.20, 0.134,
0.023, and 0.014%, respectively (Fig. 1C and
Supplementary Table S3). When generating the ampli-
con sequences for the NLRP3 exons, the target se-
quence (CDS region and ﬂanking intron in 10-bp
length) was designed to be 3002400 bp and not ad-
jacentto primer sequences in order to obtain relatively
low sequencing error rates (Fig. 1C). However, when
the base- and strand-speciﬁc error rates of the respect-
ive amplicons were compared, we noticed that there
were large variations in the error rate among ampli-
cons in a strand-speciﬁc manner (Fig. 1D). We further
examined the occurrence pattern of sequencing
errors, as shown in Fig. 1E; the average sequencing
error rates at each base in the 50 control amplicons
are shown in a bar graph, where the bars in the
upper or lower direction show the sequence error
rates at the base position on the upper or lower
strand of the amplicons, respectively. As evident in
Fig. 1E, the error rates at most residues were low
(,1%) with some hotspots for each type of error.
Most of the insertion/deletion errors preferentially oc-
curred at a homonucleotide region (yellow regions in
Fig. 1E) as previously described,
17 but it was not
always the case for all of homonucleotide regions. We
could not ﬁnd any tight relationship between other se-
quence patterns and the error rate. In addition, there
was almost no position where sequencing errors oc-
curred at a similar rate on both strands. This is more
clearly shown in Fig. 1F, which indicates the numbers
of positions with sequence variations in both strands
thatwere higher than thethreshold along the horizon-
tal axis. These results indicate that the sequence errors
can be discriminated from real genetic alterations
when the sequence is read in both directions.
However, it is important to keep in mind that PCR
errors are not distinct from real genetic alterations.
We did not observe any base substitution at a rate
higher than 1% in our experiments (Fig. 1F), and the
overall PCR error rate under MPS conditions was
lower than 1% as long as a high-ﬁdelity DNA polymer-
ase was used to generate the amplicons.
Because Gilles et al.
16 recently reported that the oc-
currence of sequencing errors using the Roche 454
GS-FLX DNA sequencer depends on various factors,
we ﬁrst examined variations in the sequencing
error rates of NLRP3 exons among samples in the
same run. For each mutation category, we found a
similar trend in the error distribution rate in the
amplicon sequences among the control samples
(Supplementary Figs S2–S4). We conﬁrmed that, for
almost all residues, the error rate distributions
among the 50 control samples ﬁtted a Poisson distri-
bution (data not shown). We next examined the run-
to-run variation of the sequencing error rate for
NLRP3 exons. For this purpose, we performed an add-
itional MPS run with seven amplicons (exons 3, 4, and
6) that were newly prepared and compared the
number and positions of the sequencing errors
between two independent sequencing runs. Out of
1993 base positions in the target regions, there was
a low occurrence rate of mismatch errors in both
runs and this seemed to ﬁt a Poisson distribution.
However, insertion/deletion errors (.1% error rate)
were observed at 100 base positions (,5% in the
target regions) in each run, and only a half of these
errors were shared between both runs (Table 1).
Table 1. Run-to-run variations in the error occurrence (.1% frequency)
Error category Upper strand Lower strand All
a
First run Second run Overlap First run Second run Overlap
Insertions 63 73 42 76 96 52 10
Deletions 36 44 24 29 65 20 2
Mismatches 0 0 0 3 0 0 0
Ambiguous base calls 6 8 6 12 10 10 0
aThe number of positions where the error rates in each category were commonly .1% for both strands in two independent
runs.
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deletion errors was considerably affected by the run
conditions (probably due to variations in the absolute
signal strengths of pyrosequencing). Thus, as previous-
ly reported, the detection of insertion/deletion muta-
tions by MPS on the 454 GS-FLX system was quite
error-prone at least at a limited number of residues.
However, the results also implied that false-positive
mosaic mutations could be avoided by considering
the sequencing data for both strands because these
run-dependent insertion/deletion errors occur only
in a single strand. Taken together, we conclude that
the obtained sequence error map is stable and sufﬁ-
ciently robust to discriminate substitution sequencing
errors from low-level mosaicism.
3.2. Discrimination formula for detection of somatic
mosaicism with statistical conﬁdence
We next examined known SNPs, known heterozy-
gous mutations and somatic mosaic mutations of
CAPS patients using MPS. All of these variations
appeared on both strands at the expected allele
frequencies as shown in Fig. 2, again indicating that
ﬁltering the strand-speciﬁc sequence variations is
unlikely to eliminate real genetic variations.
Based on the experimentally observed sequencing
errors with the 454 GS-FLX system described above,
we established a discrimination formula to detect
low-level somatic mosaicism as follows. In previous
studies, the number of reads with the sequence
error of a certain category in a sequence position
was modelled based on the Poisson distribution with
two parameters l and k where the expected number
of reads containing an error and the observed
number of reads containing a sequence alteration, re-
spectively, are as shown below
18:
Poisðk;lÞ¼
lke l
k!
: ð1Þ
This model assumes that the error rate is constant
across the different sequence regions but our data
described above pointed out that the sequence error
rate varies with the sequence content.
19 Thus, we
introduced a position- and strand-speciﬁc error rate
qi,j,d for a certain error category j in amplicon position
i with strand d based on the sequencing data from 50
control samples. With the error rate qi,j,d, the upper
probability (P) that the number of reads (R) with a
certain sequence alteration of category j in position
i is equal or greater than the number of observed
reads r out of N reads with a sequenced direction d
for an unknown sample was deﬁned as:
PðR   ri;j;djli;j;dÞ¼1  
X r 1
k¼0
lk
i;j;de li;j;d
k!
; ð2Þ
where, li,j,d ¼ Ni,d   qi,j,d.
For the mismatch error rate, we did not consider
the type of base substituted in an amplicon position
in this study. We took (1 2 P) as a measure of the stat-
istical conﬁdence of the data and conventionally set a
threshold of the statistical conﬁdence to be 99.9%. In
other words, if P-value was ,0.001, the sequence al-
teration was considered to be a real sequence vari-
ation, not an error. For the ﬁnal identiﬁcation of real
genetic variation with low-level somatic mosaicism,
we determined that both of the P-values for the ith
residue in the upper and lower strands must be
smaller than the threshold.
To evaluate the lower detection limit for the allele
frequencies of somatic mosaicism based on the statis-
tical formulation shown above, we generated a series
of known allele frequencies by diluting DNA from
CAPS patients carrying heterozygous NLRP3 muta-
tions (c.1043C.T, c.1316C.T, and c.1985T.C)
with DNA from normal donors carrying the wild-
type NLRP3 gene. In the dilution series, the mutant
allele frequencies were adjusted to be 10, 5, 3, 2, 1,
and 0.5% (Table 2). The data indicated that somatic
mosaicism at these sites and at an allele frequency
 1% could be convincingly detected with statistical
signiﬁcance (P, 0.001) if more than 350 reads for
each strand were obtained for an amplicon. We also
applied this statistical method to detect somatic mo-
saicism in patients with known low-level mosaic
mutations described above and conﬁrmed that all of
Figure 2. Scatter plot of the observed frequency variation in both
strands. The colours depict known SNPs (green), heterozygous
and mosaic mutations (orange) and errors (grey).
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niﬁcance without any false positives (data not shown).
3.3. Detection and characterization of NLRP3 somatic
mosaicism using the MPS platform
To demonstrate the power of this approach in prac-
tice, we applied our new pipeline for 10 CINCA/
NOMID patients in whom we failed to detect muta-
tions in the NLRP3 gene using a conventional direct
DNA sequencing approach. The mutations detected
by the analysis formulated using the MPS platform
in this study are listed in Table 3. We successfully
identiﬁed four out of the 10 patients with NLRP3
somatic mosaicism, which was conﬁrmed by subclon-
ing and Sanger sequencing. The nucleotide substitu-
tions were as follows (parentheses indicate the
corresponding amino acid change): c.907G.C
(p.Asp303His), c.1699G.A (p.Glu567Lys) in two
patients, and c.906C.A (p.Phe302Leu). The frequen-
cies of mosaicism identiﬁed in these patients by the
MPS approach were consistent with those that were
identiﬁed by the subcloning and subsequent capillary
DNA sequencing method (data not shown). Both
c.907G.C and c.1699G.A variants were reported
as CINCA/NOMID-associated mutations in Infevers
database (http://fmf.igh.cnrs.fr/ISSAID/infevers/) and
in the dbSNP database (http://www.ncbi.nlm.nih.gov/
projects/SNP/).
8
Because the NLRP3 p.Phe302Leu mutation was
novel and not detected in the 50 healthy controls, we
performed an in vitro functional analysis to see the
effect of p.Phe302Leu on the protein function. We
used two different in vitro transfection experiments,
Table 2. Evaluation of the lower detection limit for mosaicism with three sets of dilution series
Mutation Dilution (%) Upper strand Lower strand
Total
reads
Mutant
reads
%Mutant P-value Total
reads
Mutant
reads
%Mutant P-value
c.1043C.T; p.Thr348Met 10.0 724 61 8.43 8.62E2130 520 57 10.96 1.73E2117
5.0 453 24 5.30 2.86E247 372 15 4.03 1.26E225
3.0 876 27 3.08 1.16E246 757 21 2.77 6.83E232
2.0 737 10 1.36 1.05E214 645 7 1.09 8.68E209
1.0 715 9 1.26 4.73E213 624 4 0.64 1.11E204
0.5 1025 7 0.68 1.15E214 756 3 0.40 3.22E203
a
c.1431C.A; p.Asn477Lys 10.0 542 65 11.99 1.22E2113 346 24 6.94 6.84E249
5.0 491 30 6.11 1.13E244 356 17 4.78 2.42E232
3.0 487 21 4.31 1.26E228 374 19 5.08 1.78E236
2.0 577 18 3.12 2.78E222 495 9 1.82 4.57E214
1.0 491 4 0.82 9.17E204 354 5 1.41 7.34E208
0.5 483 0 0 NA 424 3 0.71 NA
c.1985T.C; p.Met662Thr 10.0 658 79 12.01 1.13E2179 643 74 11.51 4.64E2167
5.0 643 31 4.82 2.56E259 608 33 5.43 9.96E265
3.0 777 27 3.48 4.65E248 704 29 4.12 1.26E253
2.0 929 21 2.26 7.59E234 835 15 1.80 3.92E223
1.0 735 17 1.09 2.74E211 709 9 1.27 4.06E213
0.5 702 2 0.29 3.90E203
a 590 1 0.17 1.37E201
a
aNot signiﬁcant.
Table 3. Potential mosaic mutations detected in patients with unknown mutations
Patient ID Amplicon # Variation % Variation
frequency
P-value dbSNP State
Forward Reverse Forward Reverse
P1 Exon3_2 c.907G.C p.Asp303His 7.12 11.56 3.0E244 1.7E284 rs121908153 Known
P2 Exon3_5 c.1699G.A p.Glu567Lys 5.94 5.79 2.0E269 8.9E247 — Known
P3 Exon3_5 c.1699G.A p.Glu567Lys 18.28 15.33 0.0E þ 00 1.0E2312 — Known
P4 Exon3_2 c.906C.A p.Phe302Leu 9.78 9.70 1.7E286 2.2E2122 — Novel
No. 2] K. Izawa et al. 149the rapid cell death in transfected THP-1 cells and the
ASC-dependent NF-kB activation in transfected
HEK293FT cells (Fig. 3A and B, respectively). Both
assays clearly showed that p.Phe302Leu was a disease-
causing mutation similar to known CINCA/NOMID-
associated pathogenic mutations (p.Asp303His and
p.Glu567Lys).
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4. Discussion
Although the somatic mutation rate at the nucleo-
tide level in vivo was difﬁcult to quantitatively
measure due to the complexity of the genome and la-
borious molecular detection processes, recent
advances in MPS technologies have allowed us to dir-
ectly quantitate somatic mutations in human
genome.
20–22 The current estimate for the somatic
(de novo) mutation rate is 1–2   10
28 residues/gen-
eration/haploid, and this estimate is sufﬁciently low
that we would expect to never observe somatic mosai-
cism in the NLRP3 gene by chance; although the error
rate of the high-ﬁdelity DNA polymerase used to
produce the amplicons is two orders of magnitude
larger than the somatic mutation rate,
23,24 we could
not detect PCR-generated mosaicism higher than 1%
in the 454 sequencing error maps. Based on the
literature, the single base substitutions are the most
frequent type of somatic mutations (500 times
more frequent than short insertions/deletions)
25
and protein-coding sequences are less mutagenic
than sequences in non-coding regions, assuming
that the somatic mutation spectrum in malignant
cells is the same as in normal cells. Somatic mosaicism
is thought to result from de novo gain-of-function-type
mutations that are introduced at a very early and
limited stage of development, and it is reasonable to
focus our efforts on detecting base substitutions for
somatic mosaicism in the NLRP3 gene.
It is challenging but highly important in many areas
of research, such as cancer, to detect low-level
somatic mutations, which we designated as somatic
mosaicism in this study, from apparently mutation-
negative samples by conventional sequencing.
Subcloning followed by the capillary DNA sequencing
has been a de facto standard to identify somatic mo-
saicism, but this is not the method of choice for
routine diagnostics because it is laborious, time con-
suming, and costly. Thus, it is reasonable for us to
explore MPS as a new tool for this purpose. Although
previous studies have used MPS technology to detect
somatic mosaicism, it was unclear how sensitive this
method is to detect a low-level somatic mosaicism
using the MPS platform because this platform is gen-
erally error-prone. To address this challenge, we devel-
oped a new pipeline to detect low-level somatic
mosaicism with statistical conﬁdence using base pos-
ition- and strand-speciﬁc error rate maps for the
NLRP3 amplicons to be studied. Whereas the
Figure 3. In vitro functional analysis of the identiﬁed NLRP3 mosaic
mutations. (A) Rapid cell death in transfected THP-1 cells. A
GFP-fused wild-type or mutant NLRP3 was transfected into THP-
1 cells and incubated with PMA (10 ng/ml) for 4 h. The
percentage of dead cells (7-amino-Actinomycin D [7-AAD]-
positive) among the GFP-positive cells is shown. Data represent
the means+SD of triplicate experiments and are representative
of two independent experiments. The data for previously
reported mutations as well as the mutations found in this study
are shown. (B) ACS-dependent NF-kB activation in transfected
HEK293FT cells. HEK293FT cells were co-transfected with wild-
type or mutant NLRP3 in the presence or absence of ASC. NF-kB
induction is shown as the fold-change compared with cells that
were transfected with a control vector without ASC (set equal to
one). Values are the means+SD of triplicate experiments, and
the data are representative of three independent experiments.
The data for previously reported mutations (p.Arg260Trp and
p.Tyr570Cys) and the mutations found in this study are shown.
For each mutation, the data obtained in the presence and
absence of ASC are shown. These ﬁndings identiﬁed
p.Phe302Leu as a novel disease-causing mutation.
150 Detection of Low-Rate Somatic Mosaicism by Massively Parallel Sequencing [Vol. 19,detection limit of somatic mosaicism depends on the
base position and the read depth of the amplicons,
the limit of detection could be as low as 1% allele fre-
quency with no false positives for substitutions (the
precision is higher than 99.9%). Our error map
shows that 98.1% of base positions (3343 out of
3407 target positions) in the NLRP3 exonic amplicons
can be detected with 1% mosaicism when more
than 350 reads were accumulated for each strand.
Although the remaining region (64 base positions
out of 3407 target positions) was too error-prone
(the error rate ranged from 0.1 to 1.7% in either
the upper or lower strand) to detect low-level mosai-
cism by MPS, medium-level mosaicism (5% or high)
could be identiﬁed in all base positions in the target
region with the same signiﬁcance level. Based on
this pipeline, we successfully identiﬁed four cases of
somatic mosaicism among 10 apparently mutation-
negative CINCA/NOMID patients. These results were
subsequently conﬁrmed by functional analysis and
subcloning followed by capillary DNA sequencing
method.
As described above, we revealed that a read depth
of 350 for each strand of each amplicon would be
sufﬁcient to detect somatic mosaicism as low as 1%
with statistical conﬁdence. This means that an analysis
of somatic mosaicism (detection limit of 1% allele fre-
quency) of the NLRP3 gene for one sample requires
350   2   14 ¼ 9800 reads with the 454 GS-FLX se-
quencer, which has a capacity to obtain 1 000 000
reads per run. Thus, we could analyse 100 patient
samples with a single run (10 h) using this MPS
platform. For this purpose, a miniaturized 454 se-
quencer might be more convenient because it could
analyse 10 patient samples at once with a reasonably
reduced running cost.
The approach used to detect somatic mosaicism is
very similar to that for low-frequency alleles in
pooled DNA samples, for which MPS applications
have been reported by many groups.
18,26,27
However, the main aim of these previous studies was
to screen for a rare allele in a population. Thus, the
discovery phase on the MPS platform must be fol-
lowed by an evaluation phase using conventional
methods. Therefore, when diagnosing somatic mosai-
cism of the NLRP3 gene based solely on the MPS plat-
form, we could not use the same approach to detect
rare alleles in a population due to its low accuracy.
The sequencing error rate on the Roche MPS platform
was sufﬁciently stable and low enough as shown in
this study. Using our pipeline, we were able to detect
1% somatic mosaicism in the NLRP3 gene with
99.9% conﬁdence. Although another research group
recently used a similar approach with a short-read
MPS,
28 the Roche long-read MPS is more suitable as
a diagnostic tool mainly because of the short run
time. If we could diagnose somatic mosaicism of the
NLRP3 gene within a reasonable time with low
labour and costs as shown in this study, the success
rate of CINCA/NOMID genetic diagnosis will increase
from 60 to 80% or higher,
9 which will greatly
advance the health and care of these patients and
prevent irreversible bone and neurological complica-
tions of disease.
This pipeline would also be efﬁcient to detect
somatic mosaicism in mutation-negative patients
with other diseases, including cancer. The error rate
map for a given gene should be constructed from au-
thentic plasmids, and used to detect somatic mosai-
cism of other genes as well as rare alleles in various
populations.
Supplementary data: Supplementary data are
available at www.dnaresearch.oxfordjournals.org.
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